孕激素抗体EP2、SP2、1E2、16在非特殊型浸润性乳腺癌的表达差异

黎三艳; 郑眉嵩; 陈余鹏; 张声; 周先荣; 陈林莺

doi:10.16016/j.1000-5404.201912016

您当前的位置：

首页 >

文章列表页 >

孕激素抗体EP2、SP2、1E2、16在非特殊型浸润性乳腺癌的表达差异

临床医学 | 更新时间：2026-01-09

- 孕激素抗体EP2、SP2、1E2、16在非特殊型浸润性乳腺癌的表达差异
- Differences in the expression of 4 progesterone receptor antibodies EP2, SP2, 1E2, and 16 in non-specific invasive breast cancers
- 第三军医大学学报 2020年42卷第10期页码：1042-1046
- 作者机构：
  
  1.433100 湖北潜江，潜江市中心医院病理科
  2.362801 福建泉州，福建省泉州市泉港区医院病理科
  3.350005 福州，福建医科大学附属第一医院病理科
- 作者简介：
  
  [陈林莺，电话：(0591)87981650，E-mail: chenly2006@126.comCHEN Linying, Tel: 86-591-87981650, E-mail:chenly2006@126.com
- 基金信息：
  
  福建省教育厅中青年教师教育科研项目(JT180185)
- DOI：10.16016/j.1000-5404.201912016
  中图分类号： R392.11;R730.23;R737.9
- 收稿：2019-12-02，
  
  修回：2020-03-10，
  
  纸质出版：2020-05-30
- 稿件说明：
移动端阅览
黎三艳, 郑眉嵩, 陈余鹏, 等. 孕激素抗体EP2、SP2、1E2、16在非特殊型浸润性乳腺癌的表达差异[J]. 第三军医大学学报, 2020,42(10):1042-1046.

Sanyan LI, Meisong ZHENG, Yupeng CHEN, et al. Differences in the expression of 4 progesterone receptor antibodies EP2, SP2, 1E2, and 16 in non-specific invasive breast cancers[J]. Journal of Third Military Medical University, 2020, 42(10): 1042-1046.
黎三艳, 郑眉嵩, 陈余鹏, 等. 孕激素抗体EP2、SP2、1E2、16在非特殊型浸润性乳腺癌的表达差异[J]. 第三军医大学学报, 2020,42(10):1042-1046. DOI： 10.16016/j.1000-5404.201912016.

Sanyan LI, Meisong ZHENG, Yupeng CHEN, et al. Differences in the expression of 4 progesterone receptor antibodies EP2, SP2, 1E2, and 16 in non-specific invasive breast cancers[J]. Journal of Third Military Medical University, 2020, 42(10): 1042-1046. DOI： 10.16016/j.1000-5404.201912016.

摘要

目的

评估4种孕激素(progesterone receptor，PR)抗体(EP2、SP2、1E2、16)在非特殊型浸润性乳腺癌(non-specific invasive breast cancers

NSIBCs)组织中的表达，为PR判读及NSIBCs患者治疗筛选出最佳抗体。

方法

采用免疫组化法检测195例NSIBCs组织芯片中4种PR抗体的表达情况，分析比较与雌激素(estrogen receptor，ER)抗体表达构成比、着色细胞百分比、染色强度、Allred score(A-score)评分及4个抗体一致性等指标。

结果

195例NSIBCs中4种PR抗体与ER的构成比(ER±/PR±)之间差异无统计学意义(

0.05)。不考虑ER表达，4种PR抗体同时阳性或阴性(PR+/-)NSIBCs比例较高(81.54%~90.77%)，且相互的一致性较好(κ值为0.634~0.804)。进一步分析4种PR抗体的肿瘤细胞平均着色细胞数、平均阳性细胞百分比评分、平均染色强度、平均A-score等指标，显示1E2各项指标明显高于其他3种抗体(

0.05)，而EP2、SP2、16三者之间差异无统计学意义(

0.05)。

结论

NSIBCs中1E2着色阳性率及强度等均高于EP2、SP2、RP16，是较理想的PR抗体。

Abstract

Objective

To detect the expression of 4 progesterone receptor (PR) antibodies (EP2

SP2

1E2

and 16) in non-specific invasive breast cancer (NSIBCs) and identify the optimal antibody for PR analysis and treatment planning for NSIBCs.

Methods

Immunohistochemistry was used to detect the expression of the 4 PR antibodies in a tissue microarray consisting of 195 tissue specimens of NSIBCs

and their constituent ratios with the expression of estrogen receptor (ER)

the percentages of stained cells

staining intensity

Allred score (A-score) and consistency were compared.

Results

The constituent ratios of the 4 PR antibodies with ER (ER±/PR±) did not differ significantly in the 195 cases of NSIBCs (

0.05). Regardless of the status of ER expression

the cases showed high rates of positivity or negativity for all the 4 PR antibodies at the same time (81.54%~90.77%) with good consistencies among the 4 antibodies (κ=0.634~0.804). Further analysis of the average number of stained cells

percentage of positive cells

staining intensity

and A-score of the 4 PR antibodies showed that all these indicators were significantly higher for 1E2 than for EP2

SP2

and 16 (

0.05)

and were not significantly differ

ent among the latter 3 antibodies (

0.05).

Conclusion

1E2 has a higher positivity rate and expression intensity in NSIBCs than EP2

SP2 and RP16

and thus can serve as an ideal PR antibody for clinical pathology tests.

关键词

Keywords

references

[Global Burden of Disease Cancer Collaboration. FITZMAURICE C, AKINYEMIJU T F, et al . Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: A systematic analysis for the global burden of disease study[J ] . JAMA Oncol, 2018, 4(11): 1553-1568. DOI: 10.1001/jamaoncol.2018.2706 http://dx.doi.org/10.1001/jamaoncol.2018.2706 ..

HWANG K T, KIM J, JUNG J, et al . Impact of breast cancer subtypes on prognosis of women with operable invasive breast cancer: A population-based study using SEER database[J ] . Clin Cancer Res, 2019, 25(6): 1970-1979. DOI: 10.1158/1078-0432.CCR-18-2782.

PRAT A, CHEANG M C, MARTÍN M, et al . Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer[J ] . J Clin Oncol, 2013, 31(2): 203-209. DOI: 10.1200/JCO.2012.43.4134.

PRAT A, PINEDA E, ADAMO B, et al . Clinical implications of the intrinsic molecular subtypes of breast cancer[J ] . Breast, 2015, 24(suppl 2): S26-S35. DOI: 10.1016/j.breast.2015.07.008.

BURSTEIN H J, LACCHETTI C, ANDERSON H, et al . Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline f ocused update[J ] . J Clin Oncol, 2019, 37(5): 423-438. DOI: 10.1200/JCO.18.01160.

HWANG K T, KIM J, JUNG J, et al . Long-term prognostic effect of hormone receptor subtype on breast cancer[J ] . Breast Cancer Res Treat, 2020, 179(1): 139-151. DOI: 10.1007/s10549-019-05456-w.

NORDENSKJÖLD A, FOHLIN H, FORNANDER T, et al . Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer[J ] . Breast Cancer Res Treat, 2016, 160(2): 313-322. DOI: 10.1007/s10549-016-4007-5.

LUMACHI F, SANTEUFEMIAD A, BASSO S M, et al . Current medical treatment of estrogen receptor-positive breast cancer[J ] . World J Biol Chem, 2015, 6(3): 231-239. DOI: 10.4331/wjbc.v6.i3.231.

TROXELL M L, LONG T, HORNICK J L, et al . Comparison of estrogen and progesterone receptor antibody reagents using proficiency testing data[J ] . Arch Pathol Lab Med, 2017, 141(10): 1402-1412. DOI: 10.5858/arpa.2016-0497-OA.

IBRAHIM M, DODSON A, BARNETT S, et al . Potential for false-positive staining with a rabbit monocl onal antibody to progesterone receptor (SP2): findings of the UK National External Quality Assessment Scheme for Immunocytochemistry and FISH highlight the need for correct validation of antibodies on introduction to the laboratory[J ] . Am J Clin Pathol, 2008, 129(3): 398-409. DOI: 10.1309/2YXRLEQVPPNRWHGA.

LAKHANI S R, ELLIS I O, SCHNITT S J, et al . WHO Classification of Tumours of the Breast. 4th ed[M ] . International Agency for Research on Cancer. Lyon: IARC press, 2012.

RHODES A, SARSON J, ASSAM E E, et al . The reliability of rabbit monoclonal antibodies in the immunohistochemical assessment of estrogen receptors, progesterone receptors, and HER2 in human breast carcinomas[J ] . Am J Clin Pathol, 2010, 134(2): 621-632. DOI: 10.1309/AJCPOG3O3KTPZQNK.

BAE Y K, GONG G, KANG J, et al . Hormone receptor expression in invasive breast cancer among Korean women and comparison of 3 antiestrogen receptor antibodies: a multi-institutional retrospective study using tissue microarrays[J ] . Am J Surg Pathol, 2012, 36(12): 1817-1825. DOI: 10.1097/PAS.0b013e318267b012.

HUANG H J, NEVEN P, DRIJKONINGEN M, et al . Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer[J ] . J Clin Pathol, 2005, 58(6): 611-616. DOI: 10.1136/jcp.2004.022772。

CALHOUN B C, MOSTELLER B, WARREN D, et al . Analytical and clinical performance of progesterone receptor antibodies in breast cancer[J ] . Ann Diagn Pathol, 2018, 35: 21-26.DOI: 10.1016/j.anndiagpath.2018.02.007.

水若鸿, 杨文涛.乳腺癌雌、孕激素受体免疫组织化学检测中的常用抗体[J].中华病理学杂志, 2015, 44(4): 229-231. DOI:10.3760/cma.j.issn.0529-5807.2015.04.003.

SHUI R H, YANG W T. Frequently used antibodies of estrogen and progesterone receptors in breast cancers by immunohistochemistry[J]. Chin J Pathol, 2015, 44(4): 229-231. DOI: 10.3760/cma.j.issn.0529-5807.2015.04.003.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

乳腺癌超声图像特征与ER、PR、CerbB-2的相关性研究

乳腺癌新辅助化疗后残留灶分型与ER、PR、HER-2的关系

乳腺癌循环肿瘤细胞与原发肿瘤临床病理特征关系的初步研究

老年乳腺癌ER、PR表达及其与临床病理的关系

基于中国人群的雌激素受体表达新分层（低/中/高）可更精准地预测HR⁺/HER2^-早期乳腺癌患者的预后